Myko San Hrvatska | Myko San Croatia

Medicinal Mushrooms Research -
History, Principles and Results

Medicinal Mushroom Research article consists of the following parts (click to jump):

Overview of scientific research of health benefits of medicinal mushrooms

Cancer research

Antiviral research

Safety of medicinal mushroom use

Important works and literature

Scientific Research of the Health Benefits of Medicinal Mushroom

The scientific interest in health benefits of medicinal mushrooms and their use has, naturally, arisen from their long use in traditional medicine.

Over more than 50 years, the experiences and knowledge of traditional medicine of the properties and use of medicinal mushrooms has been systematically tested by strictly scientific methods - at first this was centered at cancer research, but soon also the research of antiviral effects. Thus

have been determined. Research has been carried out on

This ensured that the approach to the research of this subject was modern, scientifically valid and complete.

<back to top>

Medicinal Mushroom Research Centers

The scientific research of medicinal mushrooms started in the Far East and the majority of research was done there - especially in Japan and China. This is to be expected since traditions of using mushrooms for health are much stronger in the Far East. However, other scientists - in Russia and Europe, and especially United States are also increasingly contributing.

Most important research has been done at institutions such as the

The results have been published in eminent international magazines in the field of medicine (oncology, immunology, virology…), pharmacology, biology and biotechnology. Data on medicinal mushroom research are stored in the world's leading databases (such as Medline), as are many patent documents. From 1999, a specialized scientific magazine International Journal of Medicinal Mushrooms (Begell House, New York) publishes the newest research done in laboratories worldwide.

One can easily get a glimpse of the massive scope of this field on the Internet - just google "medicinal mushrooms" or the name of an important species of medicinal mushrooms, like Ganoderma lucidum (reishi), Lentinus edodes (shiitake), Grifola frondosa (hen of the woods), etc.

<back to top>

Health Benefits of Medicinal Mushrooms Analyzed

As of 2011, scientific research into health benefits of medicinal mushrooms found that more than 600 mushroom species possess significant medicinal properties. This number is likely larger, since just a small fraction of medicinal mushroom species have been analyzed. The research of medicinal mushrooms can roughly be divided by effects into these more specific areas:

<back to top>

The History of Medicinal Mushrooms Research - Quest for a Cancer Cure

Jump to:

Medicinal mushrooms cancer cure research history
Medicinal mushroom active compounds that cure cancer
How do mushrooms work against cancer
Human clinical trials
Publications, conferences and medicinal mushroom movement

While there is significant use of medicinal mushrooms in traditional medicine for many different diseases and conditions, scientific interest was first motivated by their anticancer (antitumor) effects.

Modern research of medicinal mushrooms started in Japan when Dr. Kisaku Mori, a Japanese pioneer in the medicinal mushroom research, established the Institute of Mushroom Research in Tokyo in 1936.

Since then, the majority of research into the anti cancer effects of mushrooms was carried out in Japan. At the Research Institute of the National Cancer Centre in Tokyo, Ikekawa et al. ("and others") carried out research into the anti cancer effects of the extracts of 7 edible mushroom species on mice with sarcoma 180 publishing their findings in 1969.

Five years later Hamuro and Chihara confirmed and expanded these findings in a joint study carried out by the Institute and the well known Japanese food company Ajinomoto. The most important results of this research follow:

For some extracted components the rate of cancer regression was 100%, with cancer regression in all cases.

Mori (father and son), Ikekawa, Hamuro, Chihara, Maeda, Taguchi, Nanba, Aoki and many others, have irrefutably proven that some medicinal mushroom cause:

Ivan Jakopovich and Tetsuro Ikekawa Medicinal mushroom researchers

Dr. Ivan Jakopovich (Myko San) and Tetsuro Ikekawa, medicinal mushroom researchers at the 3rd International Medicinal Mushroom Conference, USA 2005.

Working systematically for almost 40 years scientists in China (Xiao-Yu Li, Jia-Fang Wang, Q. Y. Yang and many others) have reached similar findings.

In fact, Q. Y. Yang has developed the first cancer cure in China from medicinal mushrooms in 1983 - the so-called polysaccharide peptide or PSP. It is classified as a medical drug and is still being used in China, Japan and Australia.

Ivan Jakopovich, Q.Y. Yang and Neven Jakopovich medicinal mushroom researchers

Left to right: Ivan Jakopovich, Q.Y. Yang (inventor of PSP) and Neven Jakopovich at the Yang Institute, Shanghai, 2007

<back to top> <cancer research menu>

Western scientific research

The first western scientific research into the anticancer effects of higher mushrooms was done by Lucas et al. at the University of Michigan (USA), in the late 1950s. They confirmed that the giant puffball (Calvatia gigantea) can be used in fighting cancer and isolated the active substance calvacin.

J. L. Hartwell composed the first extensive overview of traditional folk medications used against cancer in 1967 (Plants Used Against Cancer: A Survey). It contained plants, edible, inedible and even some poisonous mushrooms. This first precise study was the result of direct collaboration between Lucas and K. Mori.

Scientific research in the West has significantly increased since 1999 when prof. Solomon Wasser started the International Journal of Medicinal Mushrooms and the biennially held International Medicinal Mushroom Conferences. However, the majority of research in the medicinal mushroom field is still done by the Far Eastern scientists.

<back to top> <cancer research menu>

Anticancer Compounds of Mushrooms

Chihara et al. were the first to isolate lentinan (and several other anticancer substances) from the shiitake mushroom (Lentinus edodes) in 1970. They found that this remarkable high molecular weight polysaccharide can halt sarcoma 180 with 90-100% effectiveness and lead to its complete regression. Lentinan is a registered anticancer medical drug from mushrooms in Japan.

Equally effective is PSK (trade name: Krestin) from the mushroom Trametes (old: Coriolus) versicolor. This compound was found to be extremely safe. Used from the mid 1980 in Japan it is still used as a medical drug and cancer cure from mushrooms. Its popularity is best shown by the fact that in 1987 it accounted for 25% of all anticancer drug use in Japan. This drug is remarkably similar to Chinese PSP (registered as an anticancer drug in China), and is its predecessor.

Other powerful anticancer agents have also been discovered in the mycelium of certain species of mushrooms, such as KS-2 and LEM from the shiitake mushroom.

It is important to note that every mushroom species possesses literally thousands of compounds, and that many of those have more or less powerful effects. That's the reason medicinal mushroom drugs may not be as effective as less refined supplements.

Most well-known anticancer compounds of mushrooms are high molecular weight polysaccharides that boost immune system. However, more simple compounds like triterpenes (ganoderic acids) and others are also an important factor.

Compounds that work against cancer metastasis

What is particularly significant is that some anticancer agents are effective not only on primary tumors, but also have a high rate of inhibiting the emergence and development of metastases, in some cases to the point of metastases reduction and metastatic regression. Chihara et al., from the National Cancer Centre in Tokyo, proved this is true with lentinan, while Hiroaki Nanba of the Kobe Pharmaceutical University (Japan) published a report in the annals of the New York Academy of Sciences proving the same effect in the maitake D-fraction extract of the Hen of the Woods mushroom (Grifola frondosa).

Why do mushrooms contain anticancer compounds?

Where do these anticancer components of some mushrooms originate from and why are they there? Back in the 1960s, Hungarian Nobel Prize winner Szent-Györgyi, researched substances that inhibit and improve cell growth. "Retine" - the cell growth inhibitors, a derivative of highly cytotoxic (toxic to cells) methylglyoxal with strong carcinostatic (slowing cancer growth) effects are present in mushrooms in a greater concentration than "promine", promotors of cell growth. In his experiments, "retine" demonstrated anticancer effects.

The increased concentration of these anticancer compounds in mushrooms is an adaptation to their saprotrophic nutrition. Mushrooms live on dead and decaying substances, exposing them to attack from numerous parasites and fighting for nutrients. Mushrooms use growth inhibitors to combat the growth of these parasites and secure the nutrient rich areas.

<back to top> <cancer research menu>

How Medicinal Mushroom Work Against Cancer

Boosting immune system and cancer cells cytotoxicity

As previously mentioned there are many active compounds, many of which have diverse and multiple mechanisms of anticancer activity. Some of the most important and well-known modes of action are:

The most important medicinal mushroom anticancer mechanism is, undoubtedly, starting numerous immunobiological changes in the body of “host organism” (not necessarily human). This is commonly called "boosting immune system" - but it is a rather more complex function. Medicinal mushroom compounds, called biomodulators or biological response modifiers, alter the complex functioning of the immune system, strengthening both “non-specific” or general, and specific cancer immunity.

We present the immunological function modification obtained by lentinan, from shiitake mushroom, in the human body (in vivo). Thought it does not have a direct cytotoxic effect on the cancer cells lentinan acts indirectly through the host body (i.e. is “host-mediated”). Lentinan inhibits the creation of substances that weaken immune system, and strengthens the production of substances that boost immune system. Additionally, it beneficially affects the production of antibodies and increases the production of the body's own interferon proteins, activates the natural killer cells (NK cells), activates cytotoxic macrophages, speeds up the creation of interleukin-1 (IL-1) which activates lymphocytes and other interleukins, activates the classic and alternative "trajectory" of complements, and, in particular, activates cytotoxic and helper T lymphocytes...

lentinan from shiitake mushrooms chemical structure

Molecular structure of lentinan, high molecular weight polysaccharide from Lentinus edodes, shiitake mushroom
(public domain)

Similarly, PSK, schizophyllan (SPG) and other polysaccharides from mushrooms are powerful stimulants that improve the ability of defensive cells to recognize and kill various cancer cells but also, by activating many factors of humoral and cellular immunity, strengthening the function of normal cells and preventing immune system weakening.

Other medicinal mushroom compounds (specific polysaccharides, protein-bound polysaccharides, lignins, triterpenes, purines, phenolic compounds...):

Besides these, most important anticancer effects caused by a boost and modulation of immune system, active compounds from medicinal mushrooms have other beneficial effects important for cancer patients. Medicinal mushroom compounds can:

Japanese studies and clinical experience have shown that chemotherapy and cancer irradiation, in combination with certain anticancer mushroom substances, are significantly less uncomfortable and harmful, while also being much more effective. One of the most well documented effect is that the pain caused by cancer is often alleviated or entirely eliminated, cancer patient feels better, and strength and stamina are improved, as are the appetite and general health (cancer patients' general quality of life improves).

<back to top> <cancer research menu>

Medicinal Mushrooms in Human Cancer Clinical Trials

Medicinal mushroom anticancer effects have been tested in humans in a number of studies, including strictly controlled human clinical trials. Unlike thousands of cancer cell culture and animal model experiments, we can shortly discuss cancer clinical trials in humans. For ethical reasons, most of those have been carried out in combination with common anticancer therapy. These human clinical trials have invariably shown that the anticancer substances from medicinal mushrooms are most effective when used in combination with surgical treatment, chemotherapy and radiotherapy – and the results are much better than standard cancer therapy alone.

Following the results obtained through these human clinical trials, this approach of combining standard treatment and medicinal mushrooms is now the usual medical approach to cancer therapy, primarily in Japan and China.

In the early 1980s, Taguchi et al. carried out a study with 275 patients who used lentinan, a compound from shiitake medicinal mushroom, against stomach cancer (advanced or recurring - phase III).

The results: Taguchi proved that lentinan, in combination with either of two selected cytostatics,

Soon thereafter, Kasamatsu conducted a study on patients using medicinal mushrooms against cervical cancer (phase III). He proved that the medicinal mushroom compound PSK significantly prolongs life in combination with radiotherapy. Over a span of 5 years,

It was also found that PSK is making cancer cells more sensitive to radiation therapy.

Published in 1990, a controlled study carried out by Mitomi et al. on 462 patients who had undergone surgery for bowel cancer (colon and rectal) showed that PSK, in combination with a single cytostatic (type of chemotherapy drug), lead to a significantly improved "no cancer recurrence survival rate" compared with chemotherapy results alone.

In China, the aforementioned Q. Y. Yang et al. carried out a controlled study on 485 patients with esophageal, stomach and lung cancer, establishing that PSP

This kind of strictly controlled clinical trial has not yet been carried out in Europe or United States. However, Myko San completed demonstrational studies (not done in a clinical setting). Myko San studies were on a randomized single-blind sample, analyzing the official medical documentation and comparing the results with the standard therapy results published in cancer registers. The addition of medicinal mushroom anticancer therapy in patients with lung, bowel (colorectal), breast cancer

much more than using standard cancer therapy alone.

More studies have been performed, mainly in Japan and China – but, so far, only single extracted compound from just three species - Lentinus edodes, Trametes versicolor and Schyzophyllum commune – have been tested in human clinical trials. The most famous Ganoderma lucidum mushroom was even not tested.

In all cases only low, less potent dosages were used, and in almost all the therapy duration was shorter than optimal. The trials where mushrooms were used for a longer period showed the best results. However, the results of clinical studies with medicinal mushroom anticancer effects on humans are convincing, especially when compared with the results of standard chemotherapy and radiotherapy results against cancer. In most solid cancers, chemotherapy improves survival only slightly (See more: The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies); about 2%. However, relative statistics are often used for marketing purposes (when they go into 30-50%).

It has been established that, both in human clinical trials and in our studies, the effect of using medicinal mushrooms (mycotherapy) for a longer period of time has resulted in stronger improvements.

Furthermore, over 20 years of Myko San’s experience and tens of thousands of patients have assured us that better results are obtained by combining many active compounds (not single compound as in all human clinical trials) from a larger number of medicinal mushroom species – the so-called shotgun approach to mycotherapy. The careful, statistical analysis in our studies has strongly confirmed it. (read more about the approach in Myko San medicinal mushroom cancer cure in comparison with other supplements)

Finally, we found that the effects are obviously strongly dose-dependent (higher dosages lead to greatly improved effects) – and Myko San has used significantly larger doses than those used in the clinical trials. This relationship is one of the most strong proofs of actual medicinal mushroom effectiveness.

In Myko San studies,

led to greatly improved survival in lung cancer (both small and non-small lung carcinoma), bowel cancer (colon cancer and rectal cancer) and in breast cancer. Follow link for more info on Myko San cancer survival research using medicinal mushrooms.

<back to top> <cancer research menu>

Publications, Conferences and Medicinal Mushroom Movement

In August 1993, a strategic international conference on mushroom biology, production and mushroom products (First International Conference On Mushroom Biology and Mushroom Products) was hosted by the UN Educational, Scientific and Cultural Organization (UNESCO) and the Department of Biology at the Chinese University in Hong Kong. The event is clearly telling of the current significance and perspectives of medicinal mushroom field. This conference brought together most of the world's leading mycologists. One of the five theme sessions was entitled “The Nutritional and Medicinal Properties of Mushrooms”.

In 2001 Professor Solomon P. Wasser and Shu-Ting Chang, two of the most famous contemporary scientists in the medicinal mushroom field, started the International Medicinal Mushroom Conferences – worldwide scientific conferences presenting the latest findings in the fields of medicinal properties of mushrooms and their use as medicinal agents. The 1st International Medicinal Mushroom conference was held in Kiev, Ukraine (2001); followed by Pattaya, Thailand (2003); Port Townsend, USA (2005); Ljubljana, Slovenia (2007) and Nantong, China (2009). Myko San was the host and organizer of the 6th International Medicinal Mushroom Conference in Zagreb, Croatia (2011).

Solomon P. Wasser and Ivan Jakopovich medicinal mushroom researchers, at the opening of the 6th International Medicinal Mushroom Conference IMMC6

Solomon P. Wasser and Ivan Jakopovich at the opening of the 6th International Medicinal Mushroom Conference in Zagreb, 2011, hosted by Myko San.

Shu-Ting Chang and Ivan Jakopovich at the 5th International Medicinal Mushroom Conference (Exhibition of Medicinal Mushroom Products)

Shu-Ting Chang and Ivan Jakopovich at the 5th International Medicinal Mushroom Conference (Product Exhibition) in Nantong (China, 2009)

Read more about the contribution of Myko San in research of medicinal mushrooms and medicinal mushroom products against cancer (malignant tumor).

<back to top> <cancer research menu>

Medicinal Mushroom Antiviral Research

Jump to:

Health benefits of medicinal mushrooms - Antiviral effects research history
HIV cure and human clinical trials
Mechanisms of medicinal mushroom compounds against viral infections
Other viral infections. Medicinal mushrooms herpes cure research
Medicinal mushroom research of a hepatitis cure

Although the vast majority of research on the health benefits of medicinal mushroom was done on cancer, other medical conditions were also evaluated. Antiviral effects of medicinal mushrooms, being used in official traditional medicine against viral infections, was an obvious candidate for a more scientific consideration. As we'll see, there is a significant overlap of antiviral and anticancer activity, and that is because both respond to the modification and boost of our immune system medicinal mushrooms provide.

History of Mushroom Antiviral Benefits Research

Back in the 1950s Cochran and Lucas first began investigating the antiviral benefits medicinal mushrooms offer. They found that the giant puffball (C. gigantea) and the meadow mushroom (Agaricus campestris) provide protection from the poliomyelitis virus in mice.

In 1966, Cochran et al. discovered that the king bolete or porcini mushroom (Boletus edulis), the giant puffball, the Slippery Jack (Suillus luteus), shiitake mushroom (Lentinus edodes), and the birch polypore (Piptoporus betulinus) are effective against the flu causing influenza viruses.

In the mid 1970s, Yamamura and Cochran isolated the compound AC2P from shiitake mushroom that inhibits orthomyxoviridae (which include the influenza viruses). K. Mori and his son found particles in the shiitake mushroom that boost immune system through increased secretion of human interferons, as the body reacts to them as if they were of viral origin. F. Suzuki et al. further discovered that RNA from shiitake mushroom spores stimulate interferon production. Furthermore, extract from shiitake mushroom mycelia contains KS-2 compound, which provides prophylactic and therapeutic protection from the flu.

The focus on the flu and the value of these discoveries is clear when we think about the magnitude of the problem caused by seasonal flu epidemics around the world.

However, since the discovery of the deadly HIV/AIDS virus in 1981 medicinal mushroom antiviral research changed focus from the flu and most antiviral research done thereafter went into searching for an HIV cure.

According to a 1983 report by Dr. Tadao Aoki of the Shinrakuen Hospital, a 57 year old HIV-positive woman was treated with shiitake mushroom compound lentinan for the first time. She was a breast cancer patient who probably contracted HIV through blood transfusion during the surgery. At the time, shiitake mushroom active compound lentinan was already used for cancer. After a 5-month treatment period, she became HIV negative, the number of T helper lymphocyte cells (CD4 T cells) greatly improved, while the activity of natural killer (NK) cells increased from 36% to 80.8%. Three years later she was still healthy and needed no further medical treatment. Dr. Aoki described the anti-HIV (also general antiviral) activity of lentinan, a polysaccharide from the shiitake mushroom (L. edodes) in 1984 and presented the experience of the above described HIV cure at the Third International Conference on Immunopharmacology in Florence, Italy in 1985.

By late 1980s Tochikura, Nakashima and Yamamoto from the University of Yamaguchi found effective agents against four strains of HIV-1 and one strain of HIV-2. They found that lentinan sulphate blocks HIV cell to cell infection 85.9% - 96.9% in all but one strain. The extract of shiitake mycelium (LEM) inhibits cell to cell infection at virtually identical rate, in all tested strains of HIV, and so does PSK from the medicinal mushroom Turkey Tail (T. versicolor).

While it was not a 100% HIV cure, in comparison the AZT - the first official antiretroviral drug used against HIV and AIDS - was virtually ineffective against cell to cell infection (with inhibition rate of just 2.8 – 10.2%). Tochikura, Nakashima and Yamamoto published these results in 1989 in the Journal of AIDS (JAIDS) (Wolters Kluwer, New York).

The best HIV cure results from combining lentinan with antiviral drugs. For example, Kaneko et al. found that lentinan and AZT used together inhibit HIV 5 to 24 times more effectively than AZT alone.

It had also been established that PSK (from Trametes versicolor) inhibits HIV infection by modifying viral receptors, preventing the adhesion of the virus to lymphocytes, and that it has a general antiviral effect by stimulating interferon production and secretion.

In the late 1980s Dharmananda and B. K. Kim raised the attention to the fact that G. lucidum polysaccharides that boost immune system are useful to people infected with HIV.

Concurrently, several American physicians reported an improvement in the status of patients with Kaposi's sarcoma and other AIDS related symptoms after using Hen of the Woods (Grifola frondosa) extract.

<back to top> <viral infection menu>

Antiviral effects of medicinal mushrooms - Human clinical trials

In 1986 the Japanese government approved the use of lentinan in a national anti-AIDS research program. First in the study were HIV positive hemophiliacs, of which a part almost normalized lymphocyte levels in less than three months. An open test of lentinan effects on HIV followed at 16 medical schools and hospitals. Today a growing number of medical experts worldwide know that lentinan is particularly effective in stimulating and the recovery of helper T lymphocyte cells. Lentinan is the first immune system medication that improves the killer ability of natural killer T lymphocyte cells and regenerates the function of helper T lymphocyte cells whose signals activate this crucial immunological process.

Clinical testing of the use of lentinan in fighting AIDS was launched in the USA in 1989. The results of a pilot study showed a 30% increase in the number of helper T4 lymphocytes in patients.

<back to top> <viral infection menu>

Protective antiviral mechanisms

While most of the recent research was done on HIV (virus causing AIDS), the protective mechanisms, i.e. boosting immune system response, are influenced by the active compounds found in medicinal mushrooms, and equally useful in other viral diseases. And they can greatly influence and even determine the progress and the outcome of various viral diseases.

A series of studies have proven that the active substances of some mushroom species can prevent the proliferation of viruses and the development of viral infections, either directly (specific response) or through various factors of humoral and cellular immunity.

Tests on animals, cell cultures and humans with HIV/AIDS and AIDS-related diseases gave us insight into the protective antiviral mechanisms of medicinal mushrooms. Lentinan, PSK and other mushroom substances

Indirectly, but more completely, active medicinal mushroom compounds work through modification and boosting of our immune system in many complex ways. Some compounds

The importance of the increase in T4 lymphocytes, although their number remains an indicator of the progression or regression of the disease, was reduced by the discovery that HIV, which attacks macrophages and dendritic cells in lymph nodes and the skin, blocks the mechanism that informs the immune system that enough T lymphocytes have to be produced to effectively oppose viruses. Unlike T lymphocytes, macrophages continue to live when infected by HIV, and the multiplication of HIV is reduced when they are treated with immunostimulants (substances boosting immune system). Macrophage stimulation is yet another mechanism lentinan activates.

Especially important was the research of shiitake mushroom mycelium extract (LEM). We have mentioned the research carried out by Tochikura et al., which demonstrated that this shiitake mushroom extract has a very high rate of blocking cell to cell infection by various strains of HIV. Their study also demonstrated that, among other tested substances, it is equally effective in blocking extracellular HIV infections (through body fluids). By blocking both main routes of HIV infection from the start, LEM is superior to AZT, which is not only expensive, but is also very toxic to bone marrow, causing a number of dangerous side effects. Over time AZT is also increasingly less effective, and life expectancy is not extended, even if used very early on. Contrary to this, LEM is as non-toxic as normal human food, and much cheaper.

Perhaps most importantly, as established back in the late 1980s by H. Suzuki et al. of the University of Tokyo, some components of LEM, beside activating macrophages, cause the regeneration of bone marrow cells, the "birthplace" of many of our defensive immune system cells. This is caused by a derivative of lignin EP3, which also, by a rate of 90%, inhibits the creation of enzymes HIV uses to replicate in attacked cells. Even more, it also completely prevented HIV damage to very sensitive T lymphocytes.

EP3 acetyl lignin is the most effective component of LEM that simultaneously acts as a booster of immune system and antiviral agent. Based on the described Japanese success, Sharon reports that HIV-positive and AIDS patients that still do not have major symptoms of the disease take 2 g of LEM every day until the symptoms disappear without recurrence (this is assumed to take from 6 to 12 months), and then change to 650 mg per day for maintenance.

The predominant medical belief still holds that when a person becomes HIV positive, there is no return. However, as early as the mid 1980s, Jones achieved an HIV cure of a carrier (HIV positive, but showing no signs of disease) in the USA treating with LEM for just 2 months. The results showed that the viral antigen was no longer present: the patient had become HIV negative.

Ever since it was found that, in seropositive people, HIV is concealed for a long time in the lymphatic tissues before significantly damaging the defensive system, some scientists working on AIDS felt that there is no need to wait for the number of T lymphocytes to start declining, but the use of life-prolonging agents should begin immediately. That would improve the patient's chances, as a result of sufficiently early treatment with boosters of immune system and antiviral substances, of never developing AIDS symptoms.

It is, of course, imperative these medications do not devastate the organism if taken for many years, possibly decades, and perhaps on a life-long basis. Research indicates that any such HIV cure would likely have to incorporate several agents. The harmless products of shiitake and other medicinal mushrooms, along with other effective natural products that are being tested, are certainly among the first candidates for regular use in treating HIV and AIDS. However, these products have been much ignored and underestimated by the dominant combinatorial chemisty drug designing practice in Western medicine.

At the 11th World AIDS Conference, held in Vancouver, Canada in 1996, Italian immunologist M. Clerici reported on the results of a broad European AIDS study his team conducted. He estimated that as many as 30 to 50% of the people who come into contact with HIV do not become seropositive. More recent research found that, depending on the exposure route, this risk is even smaller. The reason for this is the strength of their immune system. That is another strong argument that we should, in the effort to avoid HIV infection and contracting AIDS (besides avoiding high-risk activities), reach for a harmless boost of immune system from medicinal mushrooms. This is another way to maximally reduce the risk. As we'll see in the next part, this is not limited to HIV and AIDS (although the effectiveness is variable).

<back to top> <viral infection menu>

MUSHROOMS FIGHT OTHER VIRAL INFECTIONS

Most of the mechanisms detailed above are of great benefit in fighting other viral infections. This includes directly antiviral compounds, but especially the boost of non-specific immune system response with medicinal mushrooms.

If taken prior to contact with a virus, medicinal mushrooms can provide strong preventive protection from viral infections. and assist the body in inhibiting and overcoming an existing viral infection, speeding up recovery. Medicinal mushrooms can either prevent or help the immune system better fight parainfluenza and rhinoviruses (the common cold) and prevent or cure flu (influenza), herpes simplex and herpes zoster, infectious mononucleosis (the "kissing disease" caused by Epstein-Barr virus), cytomegalovirus, various hepatitis viruses and other viral infections. The outcome depends on the natural defensive power of the body and timely use of medicinal mushrooms and their products.

So, by activating humoral and cell immunity, lentinan from shiitake mushrooms improves overall resistance and acts directly against HIV and many other viruses, including the flu, and viral infections of the upper and lower respiratory tract. LEM and its component EP3 completely prevented damage to cells infected with herpes simplex viruses (both HSV-1 and HSV-2 type). They also prevented damage to cells infected by the equine encephalitis virus and partially inhibited the mumps virus, measles and the polio virus.

In support of his application for a US patent in the 1980s, Japanese pioneer in the production and study of LEM benefits C. Iizuka showed the effects of polysaccharide components of LEM mixed with the plant growth factor zeatin. Without the mixture, only 10% of mice infected with herpes survived, but when the mice received the preparation two days after lethal doses of herpes, 75% survived. When they received the preparation two days before being infected, there was a 90% survival rate.

In the early 1990s, Koga et al. isolated LEM fraction, JLS-18, a promising herpes cure. They proved that JLS-18 fraction, when applied either locally or orally, prevents the multiplication of herpes viruses in the body effectively preventing herpes recurrence in herpes patients. Jones treated a group of people with genital herpes with LEM for three months. Genital herpes is possibly the most widespread of all sexually transmitted diseases. In his three month study, 30% genital herpes patients experienced major improvement, 30% experience moderate improvement, and genital herpes was stabilized in 10% of patients. There was no worsening of the condition in any patient. Orthodox medicine has yet to offer a suitable cure for genital herpes, an increasingly widespread type of herpes infecting millions of people worldwide.

<back to top> <viral infection menu>

HELP IN COMBATING HEPATITIS

Both Chinese and Japanese researchers have dedicated a great deal of attention to medicinal mushroom substances that protect the liver (hepatoprotective effect). Lentinan has demonstrated protective effects on the liver of animals, and LEM improved the function of the liver and the creation of antibodies in hepatitis B patients. In combination with polysaccharides from G. lucidum and C. versicolor, lentinan improved or entirely normalized liver enzymes in mice with toxic hepatitis.

Hepatitis is the most widespread viral disease, causing more than two million deaths worldwide every year, and more than 300 million people are infected. Over 30% of hepatitis patients acquire chronic hepatitis, which can cause liver cancer, cirrhosis and liver failure. Alpha interferon injections, used since 1992, lead to sustained improvements in about 40% of cases. The tests with LEM mentioned above completed at 16 Japanese clinics have shown the creation of antibodies in cases of chronic hepatitis B.

In one pilot study, a four-month treatment using LEM led to inactivation of the virus in 36.8% of chronic hepatitis patients, while in other studies LEM achieved a complete chronic hepatitis cure, with serious epidemic forms of the disease, in less than three months.

Based on the mechanism of boosting immune system, through stimulating the secretion of the body's own interferons, the creation of antibodies and the various modes of antiviral activity of medicinal mushrooms, it is logical to expect good results in fighting hepatitis C viruses and other hepatitis viruses.

Our experience has shown that proper medicinal mushroom extracts greatly speed up the recovery from certain viral infections – we have had successful herpes cures (herpes zoster and herpes simplex), limiting and preventing flu viruses, parainfluenza and rhinovirus viruses – the causes of the common cold. Especially promising are the major improvements after several months of hepatitis treatment, particularly in the case of hepatitis C (including the cases of complete hepatitis cures).

<back to top> <viral infection menu>

Safety of Medicinal Mushroom Use

Scientific research has conclusively proven the safety of using certain mushrooms and extracted compounds from them.

Important Works and Literature

  1. Adachi, K., Nanba, H., Otsuka, M., and Kuroda, H. 1988. Blood Pressure Lowering Activity Present in the Fruit Body of Grifola frondosa (Maitake), Chem. Phann. Bull. 36:1000-1006.
  2. Adachi, K., Nanba, H., and Kuroda, H. 1987. Potentiation of Host-Mediated Antitumor Activity in Mice by Beta-glucan Obtained from Grifola frondosa (Maitake), Chem. Pharm. Bull. 35;262-270.
  3. Akiyama, Y. et al. 1981. Immunological characteristics of anti-tumor polysaccharides lentinan and its analogues, as immune adjuvants. In Manipulation of Host Defense Mechanisms, Aoki, T. et al. (eds.). Amsterdam: Excerpta Medica (International Congress Series 576).
  4. Amagase H. et al. 1984. L.E.M. May be Effective Against Treating Hepatitis B Cases. Abstr. 197 Gastroenterology World Congress, Lisbon
  5. Antoniou L.D., et al. 1977. Reversal of Uraemic Impotence by Zinc. Lancet 2:895-98
  6. Aoki T. Et al. 1984. Antibodies to HTLV-1 and HTLV-3 in Sera from Two Japanese Patients:One with possible Pre-A.I.D.S. Lancet 2:936
  7. Aoki T, 1987. Low natural killer syndrome: clinical and immunologic features. Nat Immun Cell Growth Regul 6(3), 116-128
  8. Arinaga S, 1992. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 14(4), 535-53
  9. Arinaga S, 1992. Enhanced production of interleukin 1 and tumor necrosis factor by peripheral monocytes after lentinan administration in patients with gastric carcinoma. Int J Immunopharmacol 14(1), 43-47
  10. Balon TW, Jasman AP, Zhu JS. A fermentation product of Cordyceps sinensis increases whole-body insulin sensitivity in rats. J Altern Complement Med. 2002 Jun;8(3):315-23.
  11. Bao X, Fang J, Li X. Structural characterization and immunomodulating activity of a complex glucan from spores of Ganoderma lucidum. Biosci Biotechnol Biochem. 2001 Nov;65(11):2384-91.
  12. Brauer D, Kimmons T, Phillips M. Effects of management on the yield and high-molecular-weight polysaccharide content of shiitake (Lentinula edodes) mushrooms. J Agric Food Chem. 2002 Sep 11;50(19):5333-7.
  13. Benedict, RG & LR Brady. 1972. Antimicrobial activity of mushroom metabolites. J. Pharm. Sci. 61: 1820-1822.
  14. Bobek P, 1991. Cholesterol-lowering effect of the mushroom Pleurotus ostreatus in hereditary hypercholesterolemic rats. Ann Nutr Metab 35(4), 191-19
  15. Bok JW, et al. 1999. Antitumor sterols from the mycelia of Cordyceps sinensis. Phytochemistry. Aug;51(7):891-8.
  16. Borchers AT, et al. 1999. Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med. Sep;221(4):281-93. Review.
  17. Breene W. M. 1989. Nutritional & Medicinal Value of Exotic Mushrooms. Shiitake Mushrooms.The Proceeding of a National Symposium & Trade Show University of Minnesota 100-102
  18. Broadbent, D. 1966. Antibiotics produced by fungi. Bot. Rev. 32: 219-242.
  19. Brodziak L, 1984. Nutritive value of the mushroom Lentinus edodes (Berk.) Sing. (shiitake) compared with that of other edible mushrooms Rocz Panstw Zakl Hig 35(1), 59-62
  20. Chang, R. 1993. Limitations and Potential applications of Ganoderma and related fungal polyglycans in clinical ontology; First International Conference on Mushroom Biology and Mushroom products: 96
  21. Chang, R. 1994. Effective dose of ganoderma in humans. In Proc. Contributed Symposium 59A, B. 5th Intl. Mycol. Congr., Buchanan PK, Hseu RS and Moncalvo JM (eds), Taipei, p. 101-13.
  22. Chang, R. 1996. The Central Importance of the beta-glucan receptor as the basis of immunologic bioactivity of ganoderma polysaccharides, In Reishi, *Mizuno T, Kim BK (eds), II Yang Press, Seoul, p.177-9
  23. Chang, R. Y. 1996. Potential Application of Ganoderma Polysaccharides in the Immune Surveillance and Chemoprevention of Cancer. 153-160 In: Royse, D.J. (ed). 1996. Mushroom Biology and Mushroom Products. Proceedings of the Second International Congress.
  24. Cheng HH, Hou WC, Lu ML. Interactions of lipid metabolism and intestinal physiology with Tremella fuciformis Berk edible mushroom in rats fed a high-cholesterol diet with or without Nebacitin. J Agric Food Chem. 2002 Dec 4;50(25):7438-43.
  25. Cheng Q, 1992. Effect of cordyceps sinensis on cellular immunity in rats with chronic renal insufficiency Chung Hua I Hsueh Tsa Chih (Taipei) 72(1), 27-29
  26. Chen, A. W., 1997. Topical Use of Ganoderma Mushrooms. The Mushroom Growers Newsletter V (11), March 1997.
  27. Chen, J & R Jiang. 1980. A pharmacognostical study of the Chinese drug Lingzhi (Ganoderma). Acta. Pharm. Sin. 15:244
  28. Chen JR, 1993. The effects of Chinese herbs on improving survival and inhibiting anti-ds DNA antibody production in lupus mice. Am J Chin Med 21(3-4), 257-26
  29. Chen, K & W Zhang. 1987. Advances on anti-aging herbal medicines in China. Abstrcts of Chinese Medicines. 1:309-330
  30. Chen WC, 1995. Effects of Ganoderma lucidum and krestin on cellular immunocompetence in gamma-ray-irradiated mice. Am J Chin Med 23(1), 71-80
  31. Chen YJ, 1997. Effect of Cordyceps sinensis on the proliferation and differentiation of human leukemic U937 cells. Life Sci 60(25), 2349-2359 (1997)
  32. Cheng Q, 1992. Effect of cordyceps sinensis on cellular immunity in rats with chronic renal insufficiency. Chung Hua I Hsueh Tsa Chih (Taipei) 72(1), 27-29
  33. Chihara, G., Maeda, Y. Y. 1969 . Inhibition of mouse sarcoma 180 by polysaccharides from lentinus edodes, Nature, vol. 222, pg. 687.
  34. Chihara G, 1969. Study on the antineoplastic activity and analysis of active fractions of Polyporaceae, Lentinus edodes and other basidiomycetes. Nippon Rinsho 27(6), 1739-174
  35. Chihara G, 1970. Antitumor polysaccharides, lentinan and pachymaran. Saishin Igaku 25(5), 1043-1048
  36. Chihara G, et. al. 1970. Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom). Cancer Res 30(11), 2776-278
  37. Chihara G, 1987. Antitumor and metastasis-inhibitory activities of lentinan as an immunomodulator: an overview. Cancer Detect Prev Suppl 1, 423-443
  38. Chiu JH, et al.1998. Cordyceps sinensis increases the expression of major histocompatibility complex class II antigens on human hepatoma cell line HA22T/VGH cells. Am J Chin Med. 1998;26(2):159-70.
  39. Cochran K.W. et al. 1967 . Botanical Sources of Influenza Inhibitors" - Anti - Microbial Agents & Chemotherapy 515v
  40. Christov G, 1965. Studies on the antitumoral activity of Actinomycetes by the in vitro method. Dokl Bolg Akad Nauk 18(6), 573-57
  41. Cozens, D.D. et al. 1981a. The effect of lentinan on fertility and general reproductive performance of the rat. Toxicol. Lett. 9:55-64.
  42. Currie CR, Wong B, Stuart AE, Schultz TR, Rehner SA, Mueller UG, Sung GH, Spatafora JW, Straus NA. Ancient tripartite coevolution in the attine ant-microbe symbiosis. Science. 2003 Jan 17;299(5605):386-8.
  43. Cutler R.G. 1991. Anti-Oxidants & Ageing. Ann J. Clin. Nutr. 53:373S-379S
  44. Czop, J.K., Austen, K.F. 1985. A beta-Glucan inhibit able receptor on human monocytes, J. Immunol. 134, 2588-593.
  45. Daly J.N. et al. 1988. Immune & Metabolic Effects of Arginine in the Surgical Patient" . Annal Surg. 208(4):512-23
  46. Dennart, G. and D. Tucker. 1973. Antirumor polysaccharide Lentinan, a T cell adjuvant. J. Natl. Cancer lnst. 51:1729.
  47. deVere White RW, Hackman RM, Soares SE, Beckett LA, Sun B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology. 2002 Oct;60(4):640-4.
  48. Ding, G. 1987. Anti-arrhythmia agents in traditional Chinese medicines. From Abstrarts of Chinese Medicines 1:287-308.
  49. Diplock A.T. 1991. Anti-Oxidant Nutrients & Disease Prevention: An Overview. Am J. Clin Nutr. 53:189S-193S
  50. Du DJ, 1986. Antitumor activity of Cordyceps sinensis and cultured Cordyceps mycelia. Chung Yao Tung Pao 11(7), 51-54
  51. Eisman J.A. et al. 1988. Rapid Turnover of 1,25 Dihydroxy Vitamin D Receptor in Human Target Cells. Endocrinol. 122:1613-21
  52. Espenshade, M. A. & E. W. Griffith. 1966. Tumor-inhibiting basidiomycetes. isolation and cultivation in the laboratory. Mycologia 58: 511-517.
  53. Fehser J. et al. 1989. The Effect of Lentinan on Superoxide Dismutase Enzyme Activity in Vitro. Immunopharmocal. (Immunotoxical.) 11(1):55-61
  54. Feofilova EP, et al. 1998. [Lipid composition of fruiting bodies and submerged mycelium from Lentinus edodes (Berk.) Sing]. Mikrobiologiia. 1998 Sep-Oct;67(5):655-9.
  55. Finkelstein MP, Aynehchi S, Samadi AA, Drinis S, Choudhury MS, Tazaki H, Konno S. Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I. J Altern Complement Med. 2002 Oct;8(5):573-80.
  56. Flynn, V.T. 1991. Is the shiitake mushroom an aphrodisiac and a cause of longevitvy? From: Science and Cultivation of Edible Fungi (Maher, ed.). Rotterdam: Balkema.
  57. Fruehauf JP, 1982. The effect of lentinan on production of interleukin-1 by human monocytes. Immunopharmacology 5(1), 65-7.
  58. Fu, H. and Z. Wang. 1982. The clinical effects of Ganoderma lucidium spore preparations in 10 cases of atrophic myotonia. J. Trad. Chin. Med. 2:63-65.
  59. Fujita, A., et. al. 1969. Determination of vitamin D by thin layer chromatography. II. Determination of vitamin D in Shiitake Lentinus edodes. Vitamins 40: 129-135.
  60. Gan KH, et al. 1998. Mediation of the cytotoxicity of lanostanoids and steroids of Ganoderma tsugae through apoptosis and cell cycle. J Nat Prod. Apr; 61(4): 485-487.
  61. Gao, B. and G. Yang. 1991. Effects of Ganoderm pplanatum polysaccharide on cellular and humoral iImunity in normal and sarcoma 180 transplanted mice. Phythother. Res. 5:134- 138. From CA 115:85011v.
  62. Gao Q, et al. 1996. Characterisation of acidic heteroglycans from Tremella fuciformis Berk with cytokine stimulating activity. Carbohydr Res.; 288: 135-142.
  63. Gao QP, et al. 1996 Aug. Characterization and cytokine stimulating activities of heteroglycans from Tremella fuciformis. Planta Med.; 62(4): 297-302.
  64. Gao Q, et al. 1997. Characterization and cytokine-stimulating activities of acidic heteroglycans from Tremella fuciformis. Planta Med.; 63(5): 457-460.
  65. Gao Y, Zhou S, Wen J, Huang M, Xu A. Mechanism of the antiulcerogenic effect of Ganoderma lucidum polysaccharides on indomethacin-induced lesions in the rat. Life Sci. 2002 Dec 27;72(6):731-45.
  66. Garland C.F. et al. 1989. Serum 25 Hydroxy-Vitamin D & Colon Cancer: 8 Year Prospective Study. Lancet 2:1176-78
  67. Geng, S. et al. 1985. Treatment of Hyperlipidemia with Cultivated Cordyceps-A Double Blind, Randomized Placebo Control Trial. Chin. J. Integ. Med. 5(11), 652.
  68. Gentao, L & R. Xu. 1985. Immuno-pharmacologic activity of Cordyceps sinensis (berk.) Sacc. Chi J Int Trad & West Med. 21(6): 622-624.
  69. Ghafar MA, Golliday E, Bingham J, Mansukhani MM, Anastasiadis AG, Katz AE. Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report. J Altern Complement Med. 2002 Aug;8(4):493-7.
  70. Ghafar MA, Golliday E, Bingham J, Mansukhani MM, Anastasiadis AG, Katz AE. Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report. J Altern Complement Med. 2002 Aug;8(4):493-7.
  71. Ghoneum, M., M. Wimbley, F. Salem, A. Mcklain, N. Attallan, G. Gill., 1995. Immunodulatory and anticancer effects of active hemicellulose compound (AHCC). Int. Journal of Immunotherapy XI (1) 23-28.
  72. Gong, M. et al. 1990. Molecular structure and immunoactivity of the polysaccharide from Cordyceps sinensis. Shengwu Huaxue Zazl. 6:486-492. From CA 1 14:94819w.
  73. Gordon M, et al. 1998. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J Med. 29(5-6):305-30.
  74. Goulet N.R. et al. 1960. Differential & Specific of Echo Viruses by Plant Extracts" - Proc. Soc. Exp. Biol. Med. 103-96
  75. Grabski AC, et al. 1998. Immobilization of manganese peroxidase from Lentinula edodes and its biocatalytic generation of MnIII-chelate as a chemical oxidant of chlorophenols. Biotechnol Bioeng. 1998 Oct 20;60(2):204-15.
  76. Guan YJ, 1992. Effect of Cordyceps sinesis on T-lymphocyte subsets in chronic renal failure. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 12(6), 338-339
  77. Gunde-Cimerman, N.G. and A. Cimerman, 1995. Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-Coenzyme A Reductase-Lovastatin®. Experimental Mycology 19:1-6.
  78. Guo DZ, et al. 1984. Preliminary observation on carboxyl-methyl Poria cocos polysaccharide (CMPCP) in treating chronic viral hepatitis. J Tradit Chin Med. Dec 1; 4(4): 282.
  79. Haak-Frendscho M, 1993. Ling Zhi-8: a novel T cell mitogen induces cytokine production and upregulation of ICAM-1 expression. Cell Immunol 150(1), 101-11
  80. Hamano K, et al. 1999. The preoperative administration of lentinan ameliorated the impairment of natural killer activity after cardiopulmonary bypass. Int J Immunopharmacol. Aug;21(8):531-40.
  81. Hamuro J, 1994. Synergistic antimetastatic effects of lentinan and interleukin 2 with pre- and post-operative treatments. Jpn J Cancer Res 85(12), 1288-1297
  82. Harada, T., & Kanetaka, T. 1987. [oral administration of LEM with EP3 improved the hepatic functions of hepatitis-B patients in vivo without serious side effects] Kantansui, vol.14, pg.327.
  83. Hartoma T.R. et al. 1977. Zinc Plasma Androgens and Male Sterility. Lancet 2:1125-26
  84. Hatanaka K. et al. 1989. Synthesis of an Inhibitor of Human Immuno-Deficiency Virus Infection. Jpn. J. Cancer Res. 80.95-98
  85. Hattori T, et al. 1992. Studies on antinephritic effects of plant components (3): Effect of pachyman, a main component of Poria cocos Wolf on original-type anti-GBM nephritis in rats and its mechanisms. Jpn J Pharmacol. May 1; 59(1): 89-96.
  86. Hatvani N, Kredics L, Antal Z, Mecs I. Changes in activity of extracellular enzymes in dual cultures of Lentinula edodes and mycoparasitic Trichoderma strains. J Appl Microbiol. 2002;92(3):415-23.
  87. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 13:1815-20, 1993.
  88. Hazama S, 1995. Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma Gan To Kagaku Ryoho 22(11), 1595-1597
  89. Herlyn D, 1985.Monoclonal antibody-dependent murine macrophage-mediated cytotoxicity against human tumors is stimulated by lentinan. Jpn J Cancer Res 76(1), 37-42
  90. Heyland DK. In search of the magic nutraceutical: problems with current approaches. J Nutr. 2001 Sep;131(9 Suppl):2591S-5S.
  91. Hirasawa M, et al. 1999. Three kinds of antibacterial substances from Lentinus edodes (Berk.) Sing. (Shiitake, an edible mushroom). Int J Antimicrob Agents. Feb;11(2):151-7.
  92. Hishida I, 1988. Antitumor activity exhibited by orally administered extract from fruit body of Grifola frondosa (maitake). Chem Pharm Bull (Tokyo) 36(5), 1819-1827
  93. Hockaday TD. Two herbal preparations, Cordyceps Cs4 and Cogent db: do they act on blood glucose, insulin sensitivity, and diabetes as "viscous dietary fibers?". J Altern Complement Med. 2002 Aug;8(4):403-5.
  94. Hokama Y. et al. 1981. In Vitro Inhibition of Platelel Aggregation with Low dalton Compounds from Aqueous Dialysates of Edible Fungi. Res. Comm. Chem. Pathol. & Pharmacol. 31:177-80
  95. Honma, H., Oshima, S., Watanabe, S. et al. (1982). Clinical efficacy of schizophyllan (SPG) in treatment of lung cancers. A Randomized controlled study. Haigan 22: 499-512.
  96. Hong, Z. & Y. Li. 1990. Immuno-pharmacological functions of Cordyceps. Chi J Int Trad & West Med. 10(9): 570-571.
  97. Horiuchi Y, Kimura R, Kato N, Fujii T, Seki M, Endo T, Kato T, Kawashima K. Evolutional study on acetylcholine expression. Life Sci. 2003 Feb 28;72(15):1745-1756.
  98. Hu H, Ahn NS, Yang X, Lee YS, Kang KS. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 2002 Nov 20;102(3):250-3.
  99. Hugenholtz J, Smid EJ. Nutraceutical production with food-grade microorganisms. Curr Opin Biotechnol. 2002 Oct;13(5):497-507.
  100. Hsu MJ, Lee SS, Lin WW. Polysaccharide purified from Ganoderma lucidum inhibits spontaneous and Fas-mediated apoptosis in human neutrophils through activation of the phosphatidylinositol 3 kinase/Akt signaling pathway. J Leukoc Biol. 2002 Jul;72(1):207-16.
  101. Iino Y, Yokoe T, Ohwada S, et al. Eight-year results of adjuvant immunochemotherapies vs chemotherapy in the treatment of operable breast cancer. 18th *International Congress of Chemotherapy. June 27-July 2, 1993, Stockholm, Sweden, p. 162, 1993.
  102. Ikekawa T, 1969. Antitumor activity of aqueous extracts of edible mushrooms. Cancer Res 29(3), 734-735
  103. Ikumoto, T. et al 1991. Physiologically active compounds in the extracts from Tockukaso and cultured mycelia of Cordyceps and Isaria. Yakugaku Zasshi 111(9): 504-509.
  104. Inoue A, Kodama N, Nanba H. Effect of maitake (Grifola frondosa) D-fraction on the control of the T lymph node Th-1/Th-2 proportion. Biol Pharm Bull. 2002 Apr;25(4):536-40.
  105. Irinoda, K. 1992. Stimulation of microbicidal host defense mechanisms against aerosol influenza virus infection by lentinan. Int. j Immunopharmacol. 14:971-977.
  106. Ishii K, Kita T, Hirata J, et al. Antitumor effect of PSK and its combined effect with CDDP on ovarian serous adenocarcinoma-bearing nude mice. Nippon Sanka Fujinka Gakkai Zasshi 45:333-9, 1993.
  107. Ishizuka T, 1995. Effects of interferon-gamma on cell differentiation and cytokine production of a human monoblast cell line, U937. Inflammation 19(6), 627-636 (1995)
  108. Ito H, 1972. Antitumor activity of Basidiomycetes. Nippon Yakurigaku Zasshi 68(4), 429-44
  109. James, J. S. 1986. Shiitake, Lentinan, and AIDS/ARC. Aid Treatment News. 19:1-6.
  110. Ivankovic S, Hirsl N, Jakopovich I, Jurin M, 2004. Influence of medicinal mushroom preparations on mouse tumors. International Journal of Medicinal Mushrooms, Vol. 6 (2), 107-17.
  111. Jakopovich I, 2011. New Dietary Supplements from Medicinal Mushrooms: Dr Myko San—A Registration Report. International Journal of Medicinal Mushrooms, Vol. 13 (3), 307-13.
  112. Jennemann R, et al. 1999. Basidiolipids from Agaricus are novel immune adjuvants. Immunobiology. Jun;200(2):277-89.
  113. Jia, YF., Zhou, XB., Meng, H., and Zhang, LX. Effects of Ling-Zhi on hemopoietic system in mice - immunopharmacological study (11). In The research on ganoderma (part I). Zhu S. and Mori M. (eds). Shanghai Med. U. Press, Shanghai, P. 284-288.
  114. Jingyi W, et al. 1997. Observation on the effects of Chinese medicine zhenxuanyin for improving cerebral blood flow in rats with cerebral ischemia. J Tradit Chin Med. Dec;17(4):299-303.
  115. Jong, S.C., J.M. Birmingham and S.H. Pai, 1991. Immuno-modulatory substances of fungal origin. Journal of Immunol. Immunopharamacol. Vol. XI, N. 3.
  116. Jong, S.C. and J.M. Birmingham, 1992. Medicinal effects of the mushroom Ganoderma. Adv. Appl. Microbiol. 37:101-134.
  117. Jong SC, 1993. Medicinal and therapeutic value of the shiitake mushroom. Adv Appl Microbiol 39, 153-184
  118. Kabir Y, 1987. Effect of shiitake (Lentinus edodes) and maitake (Grifola frondosa) mushrooms on blood pressure and plasma lipids of spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 33(5), 341-346
  119. Kahlos, K. et al., 1996. Preliminary tests of antiviral activity of two Inonotus obliquus strains. Fitopterapia 6 (4) 344-7.
  120. Kanayama H, et al. 1983. A new antitumor polysaccharide from the mycelia of Poria cocos wolf. Chem Pharm Bull (Tokyo). Mar 1; 31(3): 1115-1118.
  121. Kanayama H, et al. 1986. [Studies on the antitumor-active polysaccharides from the mycelia of Poria cocos Wolf. I. Fractionation and purification of antitumor polysaccharide H11]. Yakugaku Zasshi. Mar 1; 106(3): 199-205. Japanese.
  122. Kanayama H, et al. 1986. [Studies on the antitumor-active polysaccharides from the mycelia of Poria cocos Wolf. II. Structural analysis of antitumor polysaccharide H11]. Yakugaku Zasshi. Mar 1; 106(3): 206-211. Japanese.
  123. Kanayama H, et al. 1986. [Studies on the antitumor active polysaccharides from the mycelia of Poria cocos Wolf. III. Antitumor activity against mouse tumors]. Yakugaku Zasshi. Apr 1; 106(4): 307-312. Japanese.
  124. Kanemoto, M. 1983. Acute Oral Toxicity Study of Lentinus Edodes Mycelial Powder (Moncelium rtm powder) in Male and Female Mice, Biotechnical Research Laboratories, Inc., Tech. Report No. 830916A, Oct. 20.
  125. Kato, T., et al. 1979. Reduction of serum X-proline-dipeptidyl-aminopeptidase activity in tumor-bearing mice and reversal of reduced enzyme activity by lentinan, an anti-tumor polysaccharide, Experimentia, vol. 35 (3), pg. 409.
  126. Kawagishi et al., 1991. "Hericenones C, D and E, Stimulators of nerve growth factor (NGF)-synthesis from the mushroom Hericium erinaceum." Tetrahedron Letters, vol. 32, no. 35, pp. 4561-4564.
  127. Kawagishi et al., 1994. Erinacines A, B, C, strong stimulators of nerve growth factor synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Letters 35 (10): 1569-1572.
  128. Kawagishi H, 1997. A lectin from mycelia of the fungus Ganoderma lucidum. Phytochemistry 44(1), 7-10
  129. Keogh E.J. and Impotence Study Group of Western Australia . 1991. Medical Management of Impotence. Mod. Med. Australia 2:51-65
  130. Kiho T, 1993. Polysaccharides in fungi. XXXII. Hypoglycemic activity and chemical properties of a polysaccharide from the cultural mycelium of Cordyceps sinensis. Biol Pharm Bull 16(12), 1291-1293
  131. Kiho T, et al. 1995. Polysaccharides in fungi. XXXV. Anti diabetic activity of an acidic polysaccharide from the fruiting bodies of Tremella aurantia. Biol Pharm Bull.; 18(12): 1627-1629
  132. Kiho T, 1996. Polysaccharides in fungi. XXXVI. Hypoglycemic activity of a polysaccharide (CS-F30) from the cultural mycelium of Cordyceps sinensis and its effect on glucose metabolism in mouse liver. Biol Pharm Bull 19(2), 294-296
  133. Kiho T, et al. 1999. Structural features and hypoglycemic activity of a polysaccharide (CS-F10) from the cultured mycelium of Cordyceps sinensis. Biol Pharm Bull. Sep;22(9):966-70.
  134. Kim, B.K., H.W. Kim and E.C. Choi, 1994. Anti-HIV effects of Ganoderma lucidum. In : Ganoderma: Systematics, Phytopathology & Pharmacology: Proceedings of Contributed Symposium 59 A,B. 5th International Mycological Congress. Vancouver.
  135. Kim, B.K., H.W. Kim and E.C. Choi, 1996. Medicinal Efficacies of Ganoderma lucidum (XV) Anti-HIV Activities of Ganoderma lucidum. 187-194. In: Royse, D.J. (ed). 1996. Mushroom Biology and Mushroom Products. Proceedings of the Second International Congress.
  136. Kim DH, et al.1999. Beta-glucuronidase-inhibitory activity and hepatoprotective effect of Ganoderma lucidum. Biol Pharm Bull. 1999 Feb;22(2):162-4.
  137. Kim HS, et al. 1999. In vitro chemopreventive effects of plant polysaccharides (Aloe barbadensis miller, Lentinus edodes, Ganoderma lucidum and Coriolus versicolor). Carcinogenesis. Aug;20(8):1637-40.
  138. Kim KC, et al. 1999. Ganoderma lucidum extract protects DNA from strand breakage caused by hydroxyl radical and UV irradiation. Int J Mol Med. Sep;4(3):273-7.
  139. Kim JR, Yeon SH, Kim HS, Ahn YJ. Larvicidal activity against Plutella xylostella of cordycepin from the fruiting body of Cordyceps militaris. Pest Manag Sci. 2002 Jul;58(7):713-7.
  140. Kim RS, 1997. Suppressive effects of Ganoderma lucidum on proliferation of peripheral blood mononuclear cells. Mol Cells 7(1), 52-5
  141. Kim SW, Hwang HJ, Xu CP, Sung JM, Choi JW, Yun JW. Optimization of submerged culture process for the production of mycelial biomass and exo-polysaccharides by Cordyceps militaris C738. J Appl Microbiol. 2003;94(1):120-6.
  142. Kobayashi H, Kumagai F, Itagaki T, Koyama T, Inokuchi N, Iwama M, Ohgi K, Irie M. Amino acid sequence and characterization of a nuclease (nuclease Le3) from Lentinus edodes. Biosci Biotechnol Biochem. 2002 Jun;66(6):1345-55.
  143. Kodama N, Komuta K, Nanba H. Can maitake MD-fraction aid cancer patients? Altern Med Rev. 2002 Jun;7(3):236-9. Review.
  144. Kodama N, Harada N, Nanba H. A Polysaccharide, Extract From Grifola frondosa, Induces Th-1 Dominant Responses in Carcinoma-Bearing BALB/c Mice. Jpn J Pharmacol. 2002 Dec;90(4):357-60.
  145. Kodama N, Komuta K, Sakai N, Nanba H. Effects of D-Fraction, a Polysaccharide from Grifola frondosa on Tumor Growth Involve Activation of NK Cells. Biol Pharm Bull. 2002 Dec;25(12):1647-50.
  146. Koh JH, Kim JM, Chang UJ, Suh HJ. Hypocholesterolemic Effect of Hot-Water Extract from Mycelia of Cordyceps sinensis. Biol Pharm Bull. 2003 Jan;26(1):84-7.
  147. Koh JH, Yu KW, Suh HJ, Choi YM, Ahn TS. Activation of macrophages and the intestinal immune system by an orally administered decoction from cultured mycelia of Cordyceps sinensis. Biosci Biotechnol Biochem. 2002 Feb;66(2):407-11.
  148. Konishi, H. 1988. Polysaccharides-contg. extracts from Heterobasidiae as anti inflammatory agents. Jpn. Kokai Tokkyo Koho 63 JP 63, 183, 537 [88,183,537].
  149. Koyama K, 1997. Antinociceptive components of Ganoderma lucidum. Planta Med 63(3), 224-227 (1997)
  150. Kubo, K., H. Aoki, & H. Nanba, 1994. Anti-diabetic activity present in the fruit body Grifola frondosa (Maitake). Biol. Pharm. Bull. 17, 8: 1106-1110.
  151. Kubo K, 1996. The effect of maitake mushrooms on liver and serum lipids. Altern Ther Health Med 2(5), 62-66
  152. Kuo YC, 1994. Growth inhibitors against tumor cells in Cordyceps sinensis other than cordycepin and polysaccharides. Cancer Invest 12(6), 611-615
  153. Kuo YC, 1996. Cordyceps sinensis as an immunomodulatory agent. Am J Chin Med 24(2), 111-125 (1996)
  154. Kupin, V. (1994) A new biological response modifier - ganoderma lucidum - and its application in oncology. In Proceedings from the 6th international symposium on ganoderma lucidum. Seoul, II Yang, p.36-37.
  155. Kurashige S, 1997. Effects of Lentinus edodes, Grifola frondosa and Pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. Immunopharmacol Immunotoxicol 19(2), 175-183
  156. Lee, SS., Chen, FD., Chang, SC., et al. 1984. In vivo anti-tumor effects of crude extracts from the mycelium of ganoderma lucidum. J. of Chinese Oncology Society 5(3): 22-28.
  157. Lei J, 1992. Pharmacological study on Cordyceps sinensis (Berk.) Sacc. and ze-e Cordyceps Chung Kuo Chung Yao Tsa Chih 17(6), 364-366
  158. Lei LS, 1993. Effects of Ganoderma polysaccharides on the activity of DNA polymerase alpha of splenocytes and immune function in aged mice. Yao Hsueh Hsueh Pao 28(8), 577-58
  159. Li SP, Su ZR, Dong TT, Tsim KW. The fruiting body and its caterpillar host of Cordyceps sinensis show close resemblance in main constituents and anti-oxidation activity. Phytomedicine. 2002 May;9(4):319-24.
  160. Lieu CW. 1992. The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells. Anticancer Res 12(4), 1211-1215
  161. Lin CY. 1999. Inhibition of activated human mesangial cell proliferation by the natural product of Cordyceps sinensis (H1-A): an implication for treatment of IgA mesangial nephropathy. J Lab Clin Med. Jan;133(1):55-63.
  162. Lin JM, 1993. Evaluation of the anti-inflammatory and liver-protective effects of anoectochilus formosanus, ganoderma lucidum and gynostemma pentaphyllum in rats. Am J Chin Med 21(1), 59-69
  163. Lin JM, 1995. Radical scavenger and antihepatotoxic activity of Ganoderma formosanum, Ganoderma lucidum and Ganoderma neo-japonicum. J Ethnopharmacol 47(1), 33-4
  164. Lin WH, 1997. Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis. J Biol Chem 272(32), 20044-20048
  165. Lin, Z.-B, 1993. Advances in the pharmacology of Tremella polysaccharides. Mushroom Biology and Mushroom Products. S.T. Chang et al., pp. 293-298. The Chinese University Press.
  166. Lin, Y. & G. Wu, 1988. Protective effect of Polyporus umbellatus polysaccharide on toxic hepatitis in mice. 9:345-348, from Abstracts of Chinese Medicines 1: 444.
  167. Lin, Y. et al., 1987. A double-blind treatment of 72 cases of chronic hepatitis with Lentinan injection. New Drugs and Clinical Remedies 6:362-363, from Abstracts of Chinese Medicines 2:325.
  168. _______, 1989. Pharmacological and gastronomic effects of fungi and its applications. Chemical Times, No.1, p. 12-21.
  169. Lin PZ, 1984. Inhibitory effect of Cordyceps on carcinogenesis of the forestomach in mice. Chung Hua Chung Liu Tsa Chih 6(5), 335-337
  170. Liu ZY, et al. 1993. [Effect of improving memory and inhibiting acetylcholinesterase activity by invigorating-qi and warming-yang recipe, Poria cocos]. *Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. Nov 1; 13(11): 675-676. Chinese.
  171. Liu, C. 1992. Effects of Cordyceps sinensis on in vitro natural killer cells. Chung-Kua, chung Hsi I Chieh Ho Tsa Chih 12: 267-269, 259.
  172. Liu YC, et al. 1995. [Effects of poria cocos on ototoxicity induced by kanamycin in guinea-pigs]. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. Jul 1; 15(7): 422-423. Chinese.
  173. Liu F, et al. 1999; Analysis of immunomodulating cytokine mRNAs in the mouse induced by mushroom polysaccharides. Life Sci. 64(12):1005-11.
  174. Liu X, Yuan JP, Chung CK, Chen XJ. Antitumor activity of the sporoderm-broken germinating spores of Ganoderma lucidum. Cancer Lett. 2002 Aug 28;182(2):155-61.
  175. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. Prevention of development of N,N'-dimethylhydrazine-induced colon tumors by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male ICR mice. Int J Mol Med. 2002 Feb;9(2):113-7.
  176. Lu ZW, 1995. Psychoneuroimmunological effects of morphine and the immunoprotection of Ganoderma polysaccharides peptide in morphine-dependent mice. Sheng Li Ko Hsueh Chin Chan 26(1), 45-49
  177. Luo J, Zhao YY, Li ZB. A new lanostane-type triterpene from the fruiting bodies of Ganoderma lucidum. J Asian Nat Prod Res. 2002 Jun;4(2):129-34.
  178. Ma J, Ye Q, Hua Y, Zhang D, Cooper R, Chang MN, Chang JY, Sun HH. New lanostanoids from the mushroom Ganoderma lucidum. J Nat Prod. 2002 Jan;65(1):72-5.
  179. Maeda YY, 1996. Two genes controlling acute phase responses by the antitumor polysacch aride, lentinan. Immunogenetics 43(4), 215-219
  180. Maeda YY & G. Chihara. 1971. Lentinen, a new immuno-accelerator of cell mediated response. Nature (London) 229: 634.
  181. Manabe N, 1996. Effects of the mycelial extract of cultured Cordyceps sinensis on in vivo hepatic energy metabolism in the mouse. Jpn J Pharmacol 70(1), 85-88.
  182. Manohar V, Talpur NA, Echard BW, Lieberman S, Preuss HG. Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice. Diabetes Obes Metab. 2002 Jan;4(1):43-8.
  183. Masayasu, N., et al. 1987. The Effects of the Alcohol Deposit Fraction LAP of LEM in Reinforcing the Macrophages Phagocytosis Ability, J. Japanese Reticuloendothelial System Res. Assoc., vol. 27(1), pp. 201-207.
  184. Matsuoka H, 1995. Usefulness of lymphocyte subset change as an indicator for predicting survival time and effectiveness of treatment with the immunopotentiator lentinan. Anticancer Res 15(5B), 2291-2296
  185. Matsuoka H, 1997. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res 17(4A), 2751-2755
  186. Mau JL, Lin HC, Chen CC. Antioxidant properties of several medicinal mushrooms. J Agric Food Chem. 2002 Oct 9;50(21):6072-7.
  187. Mitomi, T., Tsuchiya, S., Iijima, N., et al. 1992. Randomized control study on adjuvent immunochemotherapy with PSK in curatively resected colorectal cancer. Diseases of the Colon & Rectum. 35(2):123-30.
  188. Mattila P, Salo-Vaananen P, Konko K, Aro H, Jalava T. Basic composition and amino acid contents of mushrooms cultivated in Finland. J Agric Food Chem. 2002 Oct 23;50(22):6419-22.
  189. Miyamoto, T., Abe, T., Hasunuma, K. 1985. Japan Kokai Tokkyo Koho JP60, 199,80 [85,199.810] (CI. A61K7/06). Appl. 84/5,977. 24 Mar 1984.
  190. Miyazaki T, 1981. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chem Pharm Bull (Tokyo) 29(12), 3611-3616
  191. Miyakoshi H, 1984. Acting mechanisms of Lentinan in human--I. Augmentation of DNA synthesis and immunoglobulin production of peripheral mononuclear cells. Int J Immunopharmacol 6(4), 365-371
  192. Miyakoshi H, 1984. Acting mechanisms of Lentinan in human--II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon inducer. Int J Immunopharmacol 6(4), 373-379
  193. Mizoguchi, Y. et al. 1987. Protection of liver cells against experimental damage by extract of cultured Lentinus edodes mycelia (LEM). Gast. Japonica 22:459-464.
  194. Mizoguchi, Y., et al. 1987. Determination of IL-1 Activity in the Supernatant of a Macrophage Culture Treated with LEM, Kantansui, vol. 15(1), pp. 127-135.
  195. Mizoguchi, Y. 1987. The Effects of LEM on the Induction of anti-TNP-SRBC Antibody Producing Cells by PWM Stimulation, Kantansui, vol. 15(1), pp. 127-135.
  196. Mizono M, 1996. Preparation and specificity of antibodies to an anti-tumor beta-glucan, lentinan. Biochem Mol Biol Int 39(4), 679-685 (1996)
  197. Mizuno, T., 1988. Development and utilization of bioactive substances from medicinal and edible mushroom fungi. II. Ganoderma lucidum. Chemical Times 1989 (3) 50-60.
  198. Mizuno, T., Hagiwara, T., Nakamura, T., Ito, H. Shimura, K. Sumiya, T., Asakura, A. 1990. Antitumor activity and some properties of water-insoluble hetero-glycans from "Himematsutake," the fruting body of Agaricus blazei Murill. Agricultural & Biological Chemistry 54. Tokyo. pp. 2897-2905.
  199. Mizuno T, 1992. Antitumor-active polysaccharides isolated from the fruiting body of Hericium erinaceum, an edible and medicinal mushroom called yamabushitake or houtou. Biosci Biotechnol Biochem 56(2), 347-348
  200. Mizuno, T., H. Saito, T. Nishitoba, & H. Kawagishi, 1995. Antitumor active substances from mushrooms. Food Reviews International 111: 23-61.
  201. Mizuno, T. 1996. A development on anti tumor polysaccharides from mushroom fungi. FFI Journal, 167:69-85.
  202. Mlodecki H, 1968. Tryptophan content in some edible mushrooms. Rocz Panstw Zakl Hig 19(4), 453-457
  203. Mori, H.1987. Effect of immunostimulants and antitumor agents on tumor necrosis factor (TNF) production. Int. J. Immunopharmacol. 9: 881-882.
  204. Morinaga H, 1994. An in vivo study of hepatic and splenic interleukin-1 beta mRNA expression following oral PSK or LEM administration. Jpn J Cancer Res 85(12), 1298-1303
  205. Muhlbacher F. & Kapadia C. 1982. Glutamine Metabolism in Skeletal Muscle Role of Glucocorticoids. Langenbeck's Arch. Chir. 357:203 (abstr.)
  206. Murakami M, 1997. Decreased pulmonary perfusion in hypersensitivity pneumonitis caused by Shiitake mushroom spores. J Intern Med 241(1), 85-88 (1997)
  207. Murata T, 1996. Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression. Jpn J Cancer Res 87(11), 1171-1178
  208. Murcia MA, Martinez-Tome M, Jimenez AM, Vera AM, Honrubia M, Parras P. Antioxidant activity of edible fungi (truffles and mushrooms): losses during industrial processing. J Food Prot. 2002 Oct;65(10):1614-22.
  209. Nakamura K, et al.1999. Inhibitory effect of Cordyceps sinensis on spontaneous liver metastasis of Lewis lung carcinoma and B16 melanoma cells in syngeneic mice. Jpn J Pharmacol. 1999 Mar;79(3):335-41.
  210. Nakamura K. 1999. Activation of in vivo Kupffer cell function by oral administration of Cordyceps sinensis in rats.Jpn J Pharmacol. 1999 Apr;79(4):505-8.
  211. Nakano H, et al. 1999. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology. Jul-Aug;46(28):2662-8.
  212. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343(8906):1122-6, 1994.
  213. Nanba, H. 1987. The chemical structure of an antitumor polysaccharide in fruitbodies of Grifola frondosa (Maitake). Chem. Pharm. Bull. 35:1162-8
  214. Nanba, H. 1995. Results of Non-Controlled Clinical Study for Various Cancer Patients Using Maitake D-Fraction. Explore! vol. 6, no. 5: 19-21.
  215. Nanba H. 1995. Activity of maitake D-fraction to inhibit carcinogenesis and metastasis. Ann N Y Acad Sci; 768:243-5 1995
  216. Narui T, et al. 1980. A polysaccharide produced by laboratory cultivation of Poria cocos Wolf. Carbohydr Res.Dec 1; 87(1): 161-163.
  217. Nemoto Y, Satoh K, Toriizuka K, Hirai Y, Tobe T, Sakagami H, Nakashima H, Ida Y. Cytotoxic and radical scavenging activity of blended herbal extracts. In Vivo. 2002 Sep-Oct;16(5):327-32.
  218. Ng TB. 1998. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidiomycetes: Polyporaceae). Gen Pharmacol. 1998 Jan;30(1):1-4.
  219. Ng ML, Yap AT. Inhibition of Human Colon Carcinoma Development by Lentinan from Shiitake Mushrooms (Lentinus edodes). J Altern Complement Med. 2002 Oct;8(5):581-9
  220. Nunoshsiba, T., et. al. 1990. Antimutagenic activity of hoelen extracts. Sci. Eng. Rev. Doshisha Univ. 30:266-272.
  221. Odani S, et al. 1999. The inhibitory properties and primary structure of a novel serine proteinase inhibitor from the fruiting body of the basidiomycete, Lentinus edodes. Eur J Biochem. Jun;262(3):915-23.
  222. O'Dorisia M.S. et al. 1985. Vasoactive Intestinal Polypeptide & Neuropeptide Modulation of the Immuno Response. J. Immunol. 135:792S-796S
  223. Ogawa K, 1994. Study on intratumor administration of lentinan--primary changes in cancerous tissues. Gan To Kagaku Ryoho 21(13), 2101-2104
  224. Ogawa T, et al. 1999. Effects of 5'-DFUR and lentinan on cytokines and PyNPase against AH66 ascites hepatoma in rats. Anticancer Res. Jan-Feb;19(1A):375-9.
  225. Oguchi, Y. 1987. Effect of PSK on cytotoxicity against sarcoma180 in tumor-bearing mice. Anticancer Research. Pt. B 7:681-4.
  226. Ohmori T, 1986. Antitumor activity of protein-bound polysaccharide from Cordyceps ophioglossoides in mice. Jpn J Cancer Res 77(12), 1256-126
  227. Ohno N, 1985. Neutral and acidic antitumor polysaccharides extracted from cultured fruit bodies of Grifola frondosa. Chem Pharm Bull (Tokyo) 33(3), 1181-118
  228. Ohno, N., K. Iino, T. Takeyama, I. Suzuki, K. Sato, S. Oikawa, T. Miyazaki, & T. Yadomae, 1985. Structural characterization and antitumor activity of the extracts from matted mycelium of cultured Grifola frondosa.. Chem. Pharm. Bull. 33 (8) 3395-3401.
  229. Ohtsuru, M. ,l 992 Anti-Obesity Activity Exhibited by Orally Administered Powder of Maitake Mushroom (Grifola frondosa), Anshin, July, pp. 198.
  230. Okamura M, 1994. Distribution of ascorbic acid analogs and associated glycosides in mushrooms. J Nutr Sci Vitaminol (Tokyo) 40(2), 81-9
  231. Okamoto, K., et al. 1993. Antimocrobial chlorinated orcinol derivatives from mycelium of Hericium erinaceus. Phytochemistry, vol. 34, no. 5, pp. 1445-1446.
  232. Okazaki M, Adachi Y, Ohno N, Yadomae. 1995. Structure-activity relationship of (1-->3)-beta-D-glucans in the induction of cytokine production from macrophages, in vitro. Biol Pharm Bull; 18(10):1320-7.
  233. Okuda, T., Yoshioka, T., et al. 1972. Anti-complementary activity of anti-tumor polysaccharides, Nature, New Biol., vol. 238, pg. 59.
  234. Olsen R. et al. 1989. In: Bio-Medical Applications of Chiton & its Derivitives - Chilin & Chitosan Eds. S.K. Jak-Brack et al. Elsevier Science Pub. 813-28
  235. Ooi LS, Liu F, Ooi VE, Ng TB, Fung MC. Gene expression of immunomodulatory cytokines induced by Narcissus tazetta lectin in the mouse. Biochem Cell Biol. 2002;80(2):271-7.
  236. Otsuka M, 1996. Influences of a shiitake (Lentinus edodes)-fructo-oligosaccharide mixture (SK-204) on experimental pulmonary thrombosis in rats Yakugaku Zasshi 116(2), 169-173 (1996)
  237. Park EJ, 1997. Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction. Biol Pharm Bull 20(4), 417-420
  238. Pochanavanich P, Suntornsuk W. Fungal chitosan production and its characterization. Lett Appl Microbiol. 2002;35(1):17-21.
  239. Rafique M, 1995. Effects of intraportal administration of chemoimmunotherapeutic agents on natural killer cell activity in the rat liver. J Surg Oncol 60(3), 154-159
  240. Salvucci O, 1996. Differential regulation of interleukin-12- and interleukin-15-induced natural killer cell activation by interleukin-4. Eur J Immunol 26(11), 2736-2741
  241. Sasaki T, 1976. Further study of the structure of lentinan, an anti-tumor polysaccharide from Lentinus edodes. Carbohydr Res 47(1), 99-104
  242. Sato T, et al. 1998. Transformation of the edible basidiomycete Lentinus edodes by restriction enzyme-mediated integration of plasmid DNA. Biosci Biotechnol Biochem. 1998 Dec;62(12):2346-50.
  243. Scharf, M. B. et al. 1989. Comparative Effects of Prazosin and Hydrochlorothiazide on Sexual Function in Hypertensive Men. Am. J. Med. 86 Supp 18:110-112
  244. Schillings RT & HW Ruekius. 1968. Poricin, an acidic protein with anti-tumor activity from a basidiomycete. II. Crystalization, composition and properties. Arch. Biochem. Biophys. 127: 672-679.
  245. Schinella GR, Tournier HA, Prieto JM, Mordujovich D, Rios JL. Antioxidant activity of anti-inflammatory plant extracts. Life Sci. 2002 Jan 18;70(9):1023-33.
  246. Shao G, 1985. Treatment of hyperlipidemia with cultivated Cordyceps--a double-blind, randomized placebo control trial. Chung Hsi I Chieh Ho Tsa Chih 5(11), 652-65
  247. Shieh YH, Liu CF, Huang YK, Yang JY, Wu IL, Lin CH, Li SC. Evaluation of the hepatic and renal-protective effects of Ganoderma lucidum in mice. Am J Chin Med. 2001;29(3-4):501-7.
  248. Shimada Y, Morita T, Sugiyama K. Effects of Lentinus edodes on fatty acid and molecular species profiles of phosphatidylcholine in rats fed different levels of corn oil. Biosci Biotechnol Biochem. 2002 Aug;66(8):1759-63.
  249. Shi, JH. 1993. PSP for the protection of the tumorous patients during chemotherapy. In 1993 PSP Intl Symposium, Yang QY and Kwok CY (eds.), Fudan U. Press, Shanghai, p.271-2
  250. Shi YL, James AE, Benzie IF, Buswell JA. Mushroom-derived preparations in the prevention of H2O2-induced oxidative damage to cellular DNA. Teratog Carcinog Mutagen. 2002;22(2):103-11.
  251. Sia GM, et al. 1999. Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line. Phytother Res. 1999 Mar;13(2):133-7.
  252. Sliva D, Labarrere C, Slivova V, Sedlak M, Lloyd FP Jr, Ho NW. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem Biophys Res Commun. 2002 Nov 8;298(4):603-12.
  253. Smriga M, et al. 1995. Hoelen (Poria Cocos Wolf) and ginseng (Panax Ginseng C. A. Meyer), the ingredients of a Chinese prescription DX-9386, individually promote hippocampal long-term potentiation in vivo. Biol Pharm Bull. Apr 1; 18(4): 518-522.
  254. Snow E.C. 1985. Insulin & Growth Hormone Function as Minor Growth Factors that Potentiate Lymphyocyte Activation. J. Immunol. 135 Suppl.740-746.
  255. Soo, T.S., 1994. The therapeutic value of Ganoderma lucidum. Proceedings of Contributed Symposium 59 A,B. 5th International Mycological Congress. Vancouver. pp. 105-113.
  256. Soo, T. S. 1996. Effective Dosage of the extract of Ganoderma lucidum in the Treatment of Various Ailments. 177-186 In: Royse, D.J. (ed). 1996. Mushroom Biology and Mushroom Products. Proceedings of the Second International Congress.
  257. Sorimachi, K., et al. 1990. Anti-Viral Activity of Water-solubilized Lignin Derivatives in vitro, Agri. Biol. Chem., vol.54(5), pp.1337-1339.
  258. Spittler A, 1997. Effects of 1 alpha,25-dihydroxyvitamin D3 and cytokines on the expression of MHC antigens, complement receptors and other antigens on human blood monocytes and U937 cells: role in cell differentiation, activation and phagocytosis. Immunology 90(2), 286-293 (1997)
  259. Stackl W. Et al. 1988. Intracavernous Injection of Prostaglandin E1 in Impotent Men. J. Urol 140:67-68
  260. Stavinoha, W. 1993. Short term dietary supplementation with ganoderma lucidum slows development and growth of microadenomatous lesions in the colon .... Presented at the 5th international symposium on ganoderma lucidum, Seoul, Korea on June 17, 1993.
  261. Stavinoha, W., Satsangi, N., & Weintraub, S. 1995. Study of the antiinflammatory efficacy of Ganoderma lucidum. In B.-K. Kim, & Y.S. Kim (Eds.), Recent Advances in Ganoderma lucidum research (pp. 3-7). Seoul Korea: The Pharmaceutical Society of Korea. Stavinoha, W., Slana, J., Weintraub, S., & Mobley, P. (1991). The Antiinflammatory activity of Ganoderma lucidum. Third International Symposium on Ganoderma lucidum, 9-21.
  262. Suga, T., Shiio, T., Maeda, YY., Chihara, G. 1994. Anti tumor activity of lenytinan in murine syngeneic and autochthonous hosts and its suppressive effect on 3 methylcholanthrene induced carcinogenesis. Cancer Res. 44:5132-7.
  263. Sugano, N. et al. 1982. Anticarcinogenic actions of water soluble ans alcohol insoluable fractions of culture medium of Lentinus edodes mycelia. Cancer Letters 17: 109-114.
  264. Sun L, Cai H, Xu W, Hu Y, Lin Z. CaMV 35S promoter directs beta-glucuronidase expression in Ganoderma lucidum and Pleurotus citrinopileatus. Mol Biotechnol. 2002 Mar;20(3):239-44.
  265. Suzuki M, 1994. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells. Cancer Immunol Immunother 38(1), 1-8
  266. Szedlay G. Is the widely used medicinal fungus the Ganoderma lucidum (Fr.) Karst. sensu stricto? (A short review). Acta Microbiol Immunol Hung. 2002;49(2-3):235-43. Review.
  267. Taguchi T. et al. 1985. End Point Results of Phase 3 Study of Lentinan. Japanese J. Cancer Chemother. 12:366-78
  268. Taguchi, T.1987. Clinical efficacy of lentinan on patients with stomach cancer: end point results of four-year follow-up survey. Cancer Detection & Prevention. Suppl. 1:333-49.
  269. Takehara, M. et al. 1983. Antitumor effects of virus-like particles from Lentinus edodes (Shiitake) on Ehrlich Acsites Carcinoma in mice. Archiv Virology 68: 297-301.
  270. Takeshita K, 1991. Diversity of complement activation by lentinan, an antitumor polysaccharide, in gastric cancer patients Nippon Geka Gakkai Zasshi 92(1), 5-11
  271. Takeshita K, 1993. Effect of lentinan on lymphocyte subsets of peripheral blood, lymph nodes, and tumor tissues in patients with gastric cancer. Surg Today 23(2), 125-129
  272. Takatsuki F, 1995. Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities. Int J Immunopharmacol 17(6), 465-474
  273. Takeshita K, 1996. Monocyte function associated with intermittent lentinan therapy after resection of gastric cancer. Surg Oncol 5(1), 23-28
  274. Talpur NA, Echard BW, Fan AY, Jaffari O, Bagchi D, Preuss HG. Antihypertensive and metabolic effects of whole Maitake mushroom owder and its fractions in two rat strains. Mol Cell Biochem. 2002 Aug;237(1-2):129-36.
  275. Talorete TP, Isoda H, Maekawa T. Agaricus blazei (class Basidiomycotina) aqueous extract enhances the expression of c-Jun protein in MCF7 cells. J Agric Food Chem. 2002 Aug 28;50(18):5162-6.
  276. Tamura R, 1997. Effects of lentinan on abnormal ingestive behaviors induced by tumor necrosis factor. Physiol Behav 61(3), 399-410
  277. Tan YH, 1994. High concentrations of mannitol in the shiitake mushroom Lentinula edodes. Microbios 78(318), 31-35 (1994)
  278. Tani M, 1993. Augmentation of lymphokine-activated killer cell activity by lentinan. Anticancer Res 13(5C), 1773-1776
  279. Tochikura S.T. et al. 1987. Suppression Human Immuno-Deficiency Virus Replication by 3-Azido -3- Deoxythymidine in Various Human Haematopoetic Cell Lines Invitro: Augmentation by the Effect of Lentinan. JPN. J. Cancer Res. (Gann) 78:583
  280. Tochikura, T.S., et al. 1988. Inhibition (in vitro) of replication and of the cyptopathic effect of human immunodeficiency virus by an extract of the culture medium of Lentinus edodes mycelia, Med. Microbiol. Immunol., vol. 177, pp.235-244.
  281. Tokuzen, R., & Okabe, M. 1976. Combined effect of cyclocytidine and lentinan on spontaneous mammary tumors in mice, Gann, vol. 67, pg. 327.
  282. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 31:261-8, 1990.
  283. Tseng J, et al. 1992. Suppression of tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6 and granulocyte-monocyte colony stimulating factor secretion from human monocytes by an extract of Poria cocos. Chung Hua Min Kuo Wei Sheng Wu Chi Mien I Hsueh Tsa Chih. Feb 1; 25(1): 1-11.
  284. Tsunoo, A., N. N. Takemoto, H. Tsuboi, M. Kamiho, A. Nemoto, H. Sasaki, M. Uchida, 1995. Cordyceps sinensis: its diverse effects on mammals in vitro and in vivo. New Initiatives in Mycological Research: Proceedings of the Third International Symposium of the Mycological Society of Japan.
  285. Tsunoda A. & Ishida N. 1970. A Mushroom Extract as an Interferon Inducer. Ann N.Y. Acad. Sci. 173:719-26
  286. Ukai S, 1972. Antitumor activity on sarcoma 180 of the polysaccharides from Tremella fuciformis Berk. Chem Pharm Bull (Tokyo) 20(10), 2293-2294
  287. Ukai S; Kiho T; Hara C; Kuruma I; Tanaka Y 1983. Polysaccharides in fungi. XIV. Anti-inflammatory effect of the polysaccharides from the fruit bodies of several fungi. J Pharmacobiodyn, 6:12, 983-90
  288. Ukiya M, Akihisa T, Tokuda H, Hirano M, Oshikubo M, Nobukuni Y, Kimura Y, Tai T, Kondo S, Nishino H. Inhibition of tumor-promoting effects by poricoic acids G and H and other lanostane-type triterpenes and cytotoxic activity of poricoic acids A and G from Poria cocos. J Nat Prod. 2002 Apr;65(4):462-5.
  289. van der Hem LG, 1995. Ling Zhi-8: studies of a new immunomodulating agent. Transplantation 60(5), 438-443
  290. Vetter J, 1995. Mineral and amino acid contents of edible, cultivated shii-take mushrooms (Lentinus edodes) Z Lebensm Unters Forsch 201(1), 17-19
  291. Wagner, H. & A. Proksch. 1995. Immunostimulatory Drugs of Fungi and Higher Plants. In: Economic and Medical Plant research. Acadenic Press, NY.
  292. Wan, F. and D. Huango. 1992. Anti-inflammatory and analgesic actions of artificial and fermentative Ganoderma sinensis (AFGS). Chung Kuo Chung Yao Tsa Chih 10: 619-622, 640.
  293. Wang, G. 1993. Antitumor active polyaccharides from the Chinese mushroom Songshan lingzhi, the fruiting body of Ganoderma tsugae. Bioscience, Biotech. and Biochem. 57: 894-900.
  294. Wang GL, 1996. The immunomodulatory effect of lentinan Yao Hsueh Hsueh Pao 31(2), 86-90
  295. Wang SM, et al. 1998. Effects of a water-soluble extract of Cordyceps sinensis on steroidogenesis and capsular morphology of lipid droplets in cultured rat adrenocortical cells. J Cell Biochem. Jun 15; 69(4): 483-489.
  296. Wang SY, 1997. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer 70(6), 699-705 (1997)
  297. Wang LY, et al. 1993. [Studies on chemical constituents from solvent extracts of Poria cocos (Schw.) Wolf]. Chung Kuo Chung Yao Tsa Chih. Oct 1; 18(10): 613-614. Chinese.
  298. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, Lin CH. Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem. 2002 Apr;10(4):1057-62.
  299. Wasser SP, et al. 1999. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol. 1999;19(1):65-96. Review.
  300. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002 Nov;60(3):258-74. Review.
  301. Watson R.R. et al. 1986. Selenium & Vitamins A.C.E. Nutrients with Cancer Prevention Properties. J. Am Diet. Assoc. 86(4):505-10
  302. Wei L, et al. 1999. Treatment of complications due to peritoneal dialysis for chronic renal failure with traditional Chinese medicine. J Tradit Chin Med. Mar;19(1):3-9.
  303. Weigent D.A. & Blalock J.E. 1987. Interactions Between the Neuro Endocrine and Immune Systems; Common Hormones & Receptors. Immunol. Ref. 100:79-1
  304. Weng SC, Chou CJ, Lin LC, Tsai WJ, Kuo YC. Immunomodulatory functions of extracts from the Chinese medicinal fungus Cordyceps cicadae. J Ethnopharmacol. 2002 Nov;83(1-2):79-85.
  305. Winkles JA, 1998. Serum- and polypeptide growth factor-inducible gene expression in mouse fibroblasts. Prog Nucleic Acid Res Mol Biol 58, 41-78.
  306. Won, SJ., Lee, SS., Ke, YH., Lin, MT. 1989 Enhancement of splenic NK cytotoxic activity by the extracts of ganoderma lucidum mycelium in mice. J Biomed Lab Sci 2:201-213.
  307. Wrenshall LE, et al. 1999. Modulation of macrophage and B cell function by glycosaminoglycans. J Leukoc Biol. Sep;66(3):391-400.
  308. Xia, E. and Q. Chen. 198. Isolation, analysis and biological activities of the polysaccharide of Tremella Fuciformis. ACTA Mycol. Sin. 7:166-174.
  309. Xioa, L. 1987. Progress in the studies of Chinese drugs with immunological actions. Zhongchengyao Yanjiu. 3:25-27.
  310. Xiao PG, 1993. Immunological aspects of Chinese medicinal plants as antiageing drugs. J Ethnopharmacol 38(2-3), 167-17
  311. Xiong, H-Z. 1985. Clinical observations of 45 cases of chronic hepitis by the treatment with Tremella fuciformis polysaccgaride. Chin. f. Antibiot. 10:363-365.
  312. Xu RH, 1992. Effects of cordyceps sinensis on natural killer activity and colony formation of B16 melanoma. Chin Med J (Engl) 105(2), 97-101
  313. Xu WH, 1988. Water-soluble constituents of Cordyceps sinenses (Berk.) Sacc.--the nucleosides. Chung Yao Tung Pao 13(4), 34-36
  314. Xo, W. Z. et al. 1988. Effects of Cordyceps on monoamine oxidase and immunity. Sha J Trad Chinese Med 1: 48-49.
  315. Yamada, Y., H. Nanba, H. Kuroda, 1990. Antitumor effect of orally administered extracts from fruitbody of Grifola frondosa (Maitake). Chemotherapy (Tokyo) 38, 8: 790-796.
  316. Yamaguchi N, 1990. Augmentation of various immune reactivities of tumor-bearing hosts with an extract of Cordyceps sinensis. Biotherapy 2(3), 199-20.
  317. Yang BK, Kim DH, Jeong SC, Das S, Choi YS, Shin JS, Lee SC, Song CH. Hypoglycemic effect of a Lentinus edodes exo-polymer produced from a submerged mycelial culture. Biosci Biotechnol Biochem. 2002 May;66(5):937-42.
  318. Yang LY, Huang WJ, Hsieh HG, Lin CY. H1-A extracted from Cordyceps sinensis suppresses the proliferation of human mesangial cells and promotes apoptosis, probably by inhibiting the tyrosine phosphorylation of Bcl-2 and Bcl-XL. J Lab Clin Med. 2003 Jan;141(1):74-83.
  319. Yang, W, et. al. 1985. Treatment of sexual hypofunction with Cordyceps sinensis. Jiangxi Zhongyiyao 5:46-47. From: Abstracts of Chinese Medicine 1:401.
  320. Yang, QY and Wang, MM. 1995. The effect of ganoderma lucidum extract against fatigue and endurance in the absence of oxygen. In Proc. Contributed. Symposium. 59A, B. 5th Intl Mycol. Cong., Buchanan, PK., Hseu, RS and Moncalvo JM., (eds), Taipei, p.101-113.
  321. Yao, PY., Gao, ZM., Fang, ST and Ke, L. 1993. Evaluation of the subsidiary effects of taking PSP orally on the chemotherapy of stomach cancer. In 1993 PSP Intl. Symposium, Yang QY and Kwok CY (eds), Fudan U. Press, Shanghai, p.269-70
  322. Yokota, Masanorl. 1992. Koselkai Clinic, Tokyo, Japan, Observatory Trial at AntiObesfty Activity of Maitake Mushroom (Grifola frondosa), Anshin, July, pp. 202.
  323. Yoon SY, et al. 1994. Antimicrobial activity of Ganoderma lucidum extract alone and in combination with some antibiotics. Arch Pharm Res. Dec;17(6):438-42.
  324. Yoshida, J. 1989. Antitumor activity of an extract of Cordyceps sinensis (Berk.) Sacc. against murine tumor cell line. Japan J. Exper. Med. 59:157-160.
  325. Yoshino S, 1990. Effect of intrapleural and/or intraperitoneal lentinan therapy in carcinomatous pleuritis and peritonitis Gan To Kagaku Ryoho 17(8), 1588-159
  326. Yu SJ, 1996. Fu-Ling (Poria cocos), a Chinese herbal drug, modulates cytokine secretion by human peripheral blood monocytes. Int J Immunopharmacol 18(1), 37-4
  327. Zee-Cheng RK. 1992. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find Exp Clin Pharmacol. Nov 1; 14(9): 725-736. Review.
  328. Zhang GL, Wang YH, Ni W, Teng HL, Lin ZB. Hepatoprotective role of Ganoderma lucidum polysaccharide against BCG-induced immune liver injury in mice. World J Gastroenterol. 2002 Aug;8(4):728-33.
  329. Zhang H, 1990. Immunopharmacological effect of Cordyceps sinensis Chung Hsi I Chieh Ho Tsa Chih 10(9), 570-571 (1990)
  330. Zhang J, 1994. Antitumor active protein-containing glycans from the Chinese mushroom songshan lingzhi, Ganoderma tsugae mycelium. Biosci Biotechnol Biochem 58(7), 1202-1205
  331. Zhang, L. and M. Yu, 1993. Influence of ling zhi on natural killer cells-Immunopharmacological study (5). From The research on Ganoderma lucidum (part one). Shanghai: Shanghai Medical University Press, pp. 246-253.
  332. Zhang LX, 1993. Effect of Japanese Ganoderma Lucidum on production of interleukin-2 from murine splenocytes Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 13(10), 613-615
  333. Zhang J, et al. 1994 Jul. Antitumor polysaccharides from a Chinese mushroom, "yuhuangmo," the fruiting body of Pleurotus citrinopileatus. Biosci Biotechnol Biochem.; 58(7): 1195-1201.
  334. Zhang P, Zhang L, Cheng S. Solution properties of an alpha-(1-->3)-D-glucan from Lentinus edodes and its sulfated derivatives. Carbohydr Res. 2002 Feb 5;337(2):155-60.
  335. Zhang P, Cheung PC. Evaluation of sulfated Lentinus edodes alpha-(1-->3)-D-glucan as a potential antitumor agent. Biosci Biotechnol Biochem. 2002 May;66(5):1052-6.
  336. Zhang Y, Mills GL, Nair MG. Cyclooxygenase inhibitory and antioxidant compounds from the mycelia of the edible mushroom Grifola frondosa. J Agric Food Chem. 2002 Dec 18;50(26):7581-5.
  337. Zhao CS, Yin WT, Wang JY, Zhang Y, Yu H, Cooper R, Smidt C, Zhu JS. CordyMax Cs-4 improves glucose metabolism and increases insulin sensitivity in normal rats. J Altern Complement Med. 2002 Jun;8(3):309-14.
  338. Zhao Y, 1991. Inhibitory effects of alcoholic extract of Cordyceps sinensis on abdominal aortic thrombus formation in rabbits. Chung Hua I Hsueh Tsa Chih (Taipei) 71(11), 612-615
  339. Zhao X, 1993. Cordyceps sinensis in protection of the kidney from cyclosporine A nephrotoxicity. Chung Hua I Hsueh Tsa Chih 73(7), 410-41
  340. Zhen F, 1992. Mechanisms and therapeutic effect of Cordyceps sinensis (CS) on aminoglycoside induced acute renal failure (ARF) in rats. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 12(5), 288-29
  341. Zhou L, 1990. Short-term curative effect of cultured Cordyceps sinensis (Berk.) Sacc. Mycelia in chronic hepatitis B. Chung Kuo Chung Yao Tsa Chih 15(1), 53-55
  342. Zhu JS, et al. 1999. The scientific rediscovery of a precious ancient Chinese herbal regimen: Cordyceps sinensis: part II. J Altern Complement Med. 1998 Winter;4(4):429-57.
  343. Zhu M, et al. 1999. Triterpene antioxidants from ganoderma lucidum. Phytother Res. Sep;13(6):529-31.